Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Rapport Therapeutics Inc (NASDAQ:RAPP) from $65 to $75. BTIG analyst Kambiz Yazdi maintained a Buy rating. Rapport Therapeutics shares closed at $42.68 on Tuesday. See how other analysts view this stock. Ascendiant Capital boosted Allarity Therapeutics Inc (NASDAQ:ALLR) price target from $10.25 to $11. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Allarity Therapeutics shares closed at $1.11 on Tuesday. See how other…
Oracle Corporation (NYSE:ORCL) will release its first earnings report after the closing bell on Thursday, Sept. 10. The database software provider has beaten analyst revenue estimates in two straight quarters and in four of the last 10 quarters overall. Analysts…
The market’s favorite measure of volatility, the VIX Index, closed in the low 14- to 17-point range throughout August. According to The Kobeissi letter, the 25-session run is the longest such streak since May 1992.Yet, with the S&P 500 inching…
Oracle Corp. (NYSE:ORCL) stock is surging on Tuesday, fueled by massive anticipation ahead of its upcoming first quarter earnings report on Thursday and recent high-profile artificial intelligence deal developments. Nasdaq futures were little changed while S&P 500 futures have shed…
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst…





